Page 155 - 2021_12-Haematologica-web

Phase I study of selinexor-DICE in relapsed PTCL and NKTL
patient with NKTL who progressed on SMILE. Although not directly comparable, in a retrospective multicenter study of 76 PTCL and NKTL patients treated with ICE chemotherapy in Singapore, we found that the overall and complete response rates were 57% and 34%, respectively, among this group of patients who were treated in the relapsed or refractory setting. The median progression- free survival for this group of patients was 4.5 months.25 Zelenetz et al. previously also reported that PTCL patients treated with ICE had an overall response rate of about 54% and a complete response rate of 31%.26 The high response rates seen in this clinical trial may warrant fur- ther investigation of the role of selinexor with DICE in patients with relapsed and refractory PTCL and NKTL.
Contributions
TT and PM developed the trial concept; TT, NS, MT, EP, MF, JYC, and STL were involved in recruiting and managing the patients on trial; CL performed the statistical analyses for the study; SXY evaluated all the scans to assess the responses; MJDY and SQT were the clinical trial coordinators involved in the data collection and running of the study; TT, PM and STL supervised the conduct of the study. All the authors reviewed the final manuscript.
Funding
The authors would like to thank the National Medical Research Council (Singapore) Clinical Trials Grants (NMRC/CTGICT/0001/2017) and Karyopharm Therapeutics for funding this study. The protocol development was supported by the American Society of Hematology, Clinical Research Training Institute (2015).
Disclosures
No conflicts of interests to disclose.
References
1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major sub- types differ by geographic locations. Non- Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9(7):717-720.
2. Vose J, Armitage J, Weisenburger D, International TCLP. International peripher- al T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical out- comes. J Clin Oncol. 2008;26(25):4124- 4130.
3. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progres- sion: spectrum of disease and rare long- term survivors. J Clin Oncol. 2013;31(16):1970-1976.
4.Hwang WY, Koh LP, Lim ST, et al. Multicenter study of comparative out- comes of hematopoietic stem cell trans- plant for peripheral T cell lymphoma and natural killer/T-cell lymphoma. Leuk Lymphoma. 2011;52(7):1382-1386.
5. Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-depen- dent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014;27:62-73.
6.Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009;32(6):E315.
7. Noske A, Weichert W, Niesporek S, et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008;112(8):1733- 1743.
8. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expres- sion and clinical prognosis. Neurosurgery. 2009;65(1):153-159; discussion 159-160.
9. van der Watt PJ, Maske CP, Hendricks DT, et al. The karyopherin proteins, Crm1 and karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer
cell survival and proliferation. Int J Cancer.
2009;124(8):1829-1840.
10.Kojima K, Kornblau SM, Ruvolo V, et al.
Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121(20):4166-4174.
11. Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Exp Cell Res. 2004;295(2):421-431.
12. Etchin J, Sanda T, Mansour MR, et al. KPT- 330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013;161(1):117-127.
13. Turner JG, Marchion DC, Dawson JL, et al. Human multiple myeloma cells are sensi- tized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009; 69(17):6899-6905.
14.Muqbil I, Aboukameel A, Elloul S, et al. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer Lett. 2016;383(2):309-317.
15.Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma. Blood. 2017;129(24):3175- 3183.
16. Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in- human phase I study of selinexor, a selec- tive inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142-4150.
17. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non- Hodgkin's lymphoma by integrated International Workshop Criteria and fluo- rine-18-fluorodeoxyglucose positron emis- sion tomography. J Clin Oncol. 2005; 23(21):4652-4661.
18. Kuruvilla J, Gutierrez, M, Shah, BD, et al.
Preliminary evidence of anti tumor activity of selinexor (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients with relapsed/refractory non-Hodgkin's lym- phoma and chronic lymphocytic leukemia. Blood. 2013;122(21):90.
19. Tan DSP, Pang, MY, Yong, WP, et al Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor selinexor (SXR) in Asian patients (pts) with advanced solid cancers. J Clin Oncol. 2015;22(15 suppl):2542.
20. Sweet K, Komrokji R, Padron E, et al. Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previ- ously untreated poor-risk acute myeloid leukemia. Clin Cancer Res. 2020;26(1):54- 60.
21. Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129 (24):3165-3174.
22. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple- class refractory multiple myeloma. N Engl J Med. 2019;381(8):727-738.
23.Machlus KR, Wu SK, Vijey P, et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017;130(9):1132-1143.
24.
25.
26.
Wang AY, Weiner H, Green M, et al. A phase I study of selinexor in combination with high-dose cytarabine and mitox- antrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018;11(1):4.
Tay T, Somasundaram N, Khoo LP, et al. Treatment outcomes of T and natural- killer/T-cell lymphoma with ifosfamide, carboplatin, etoposide (ICE) chemotherapy. Br J Haematol. 2019;185(Suppl. 1):3-202. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)- based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14(Suppl 1):i5-10.
haematologica | 2021; 106(12)
3175